Nexvet Biopharma plc
Healthcare · Pharmaceutical Preparations · L2 · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY16 | FY15 | FY14 | FY13 | |
|---|---|---|---|---|
| Revenue | — | $25,000 | $13,000 | $329,000 |
| Operating income | −$22.2M | −$20.0M | −$10.0M | −$4.5M |
| Net income | −$5.7M | −$2.7M | −$6.7M | −$3.2M |
| Total assets | $40.3M | $56.7M | $33.6M | — |
| Total liabilities | $5.2M | $3.1M | $8.7M | — |
| Equity | $35.1M | $53.6M | −$9.0M | −$2.9M |
| EPS (diluted) | — | — | — | — |
| Shares out. | 11.7M | 11.5M | 1.3M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2016- Operating margin
- —
- Net margin
- —
- Return on equity
- −16.4%
- Return on assets
- −14.2%
- Return on capital (ROCE)
- −62.8%
- Liabilities / assets
- 12.9%
- Debt / equity
- 0.15×
- Book value / share
- $3.00
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2016- Altman Z″ (distress)
- 4.81safe
- Accruals / assets
- 22.4%high accruals
- Piotroski F-Score
- 0/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 warning● 2 good- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Payne John BernardDirector | Jul 31, 2017 | D | 10,800 | $6.72 |
| Mccracken Joseph SDirector | Jul 31, 2017 | D | 16,400 | $6.72 |
| Lismore Damian T.Officer — Chief Financial Officer | Jul 31, 2017 | D | 67,750 | $6.72 |
| Kilty Cormac GDirector | Jul 31, 2017 | D | 10,800 | $6.72 |
| Horn JurgenOfficer — Chief Product Development Ofcr | Jul 31, 2017 | D | 15,750 | $6.72 |
| Heffernan MarkOfficer — Chief Executive Officer | Jul 31, 2017 | D | 109,810 | $6.72 |
| Hanna AshrafDirector | Jul 31, 2017 | D | 16,020 | $6.72 |
| Gunn George WDirector | Jul 31, 2017 | D | 42,600 | $6.72 |
| Farrell Geraldine TOfficer — VP Operations, General Counsel | Jul 31, 2017 | D | 18,980 | $6.72 |
| Brown Christopher NigelDirector | Jul 31, 2017 | D | 7,200 | $6.72 |
| Patel Rajiv ADirector | Jul 31, 2017 | D | 13,580 | $6.72 |
| Fried Richard B10% owner | Jul 31, 2017 | U | 833,845 | $6.72 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Other material eventJul 31, 2017
- Amended charter or bylaws · Shareholder vote · Other material eventJul 10, 2017
- Other material eventJul 5, 2017
- Other material eventJun 19, 2017
- Other material eventJun 16, 2017
- Other material eventJun 14, 2017
- Other material eventJun 7, 2017
- Other material eventJun 2, 2017
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 13, 2018
- 15-12BAug 10, 2017
- SC 13D/ANEXVET BIOPHARMA PLC 13D/A2Aug 8, 2017
- 4PRIMARY DOCUMENTAug 2, 2017
- 4PRIMARY DOCUMENTAug 2, 2017
- 4PRIMARY DOCUMENTAug 2, 2017
- 4PRIMARY DOCUMENTAug 2, 2017
- 4PRIMARY DOCUMENTAug 2, 2017
- 4PRIMARY DOCUMENTAug 2, 2017
- 4PRIMARY DOCUMENTAug 2, 2017
- 4PRIMARY DOCUMENTAug 2, 2017
- 4PRIMARY DOCUMENTAug 2, 2017
- 4PRIMARY DOCUMENTAug 2, 2017
- 4FORM 4 -Aug 2, 2017
- 4FORM 4 -Aug 2, 2017
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.